Cochlear (CHEOF) Stock Forecast & Price Target

Compare

32 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CHEOF Analyst Ratings

Hold

1 Buy

2 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Cochlear

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CHEOF Stock 12 Month Forecast

Average Price Target

$198.85

▲(14.27% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is $198.85 with a high forecast of $220.39 and a low forecast of $186.99. The average price target represents a 14.27% change from the last price of $174.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"163":"$163","192":"$192","221":"$221","177.5":"$177.5","206.5":"$206.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":220.38555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$220.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":198.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$198.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":186.9938,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$186.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[163,177.5,192,206.5,221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.56,172.54658076923076,176.53316153846154,180.5197423076923,184.50632307692308,188.49290384615384,192.47948461538462,196.46606538461538,200.45264615384616,204.43922692307692,208.4258076923077,212.41238846153846,216.39896923076924,{"y":220.38555,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.56,170.89000000000001,173.22,175.55,177.88,180.21,182.54,184.87,187.2,189.53,191.85999999999999,194.19,196.51999999999998,{"y":198.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,168.56,169.97798461538463,171.39596923076923,172.81395384615385,174.23193846153845,175.64992307692307,177.0679076923077,178.4858923076923,179.90387692307692,181.32186153846155,182.73984615384614,184.15783076923077,185.57581538461537,{"y":186.9938,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":178.294,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.081,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.247,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.667,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.804,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.505,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.607,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.012,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.063,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 62, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.175,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$220.39

Average Price Target$198.85

Lowest Price Target$186.99

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$187.81

Hold

7.93%

Upside

Reiterated

01/08/26

Ord Minnett Sticks to Its Hold Rating for Cochlear (CHEOF)

Laura Sutcliffe

Citi

$213.88→$200.51

Hold

15.22%

Upside

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: Cochlear (Other OTC: CHEOF) and Relmada Therapeutics (NASDAQ: RLMD)

Shane Storey

Canaccord Genuity

$220.56

Buy

26.75%

Upside

Reiterated

11/17/25

Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)

David Bailey

Morgan Stanley

$187.14

Sell

7.54%

Upside

Reiterated

10/17/25

Cautious Outlook on Cochlear: Sell Rating Due to FY26 NPAT Reliance and Nexa Implant Uncertainty

David Low

J.P. Morgan

$203.85→$232.59

Buy

33.66%

Upside

Reiterated

08/18/25

J.P. Morgan Remains a Buy on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$180.79→$197.77

Hold

13.65%

Upside

Reiterated

08/18/25

Macquarie Reaffirms Their Hold Rating on Cochlear (CHEOF)

Derek Jellinek

Morgans

$188.05→$200.2

Sell

15.05%

Upside

Downgraded

08/17/25

Cochlear (CHEOF) was downgraded to a Sell Rating at Morgans

David Stanton

Jefferies

$236.6→$237.94

Buy

36.73%

Upside

Reiterated

08/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Steven Wheen

Jarden

$180.65→$186.15

Hold

6.97%

Upside

Reiterated

08/15/25

Jarden Keeps Their Hold Rating on Cochlear (CHEOF)

Craig Wong-Pan

RBC Capital

$196.5→$197.17

Hold

13.30%

Upside

Reiterated

08/15/25

RBC Capital Reaffirms Their Hold Rating on Cochlear (CHEOF)

Marcus Curley

UBS

$217.22→$233.93

Buy

34.43%

Upside

Reiterated

08/15/25

UBS Sticks to Their Buy Rating for Cochlear (CHEOF)

Davinthra Thillainathan

Goldman Sachs

Hold

―

Reiterated

06/14/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM) and Cochlear (Other OTC: CHEOF)

Andrew Paine

CLSA

$188.81→$193.83

Buy

11.38%

Upside

Upgraded

03/17/25

CLSA Upgrades Cochlear Ltd. (COH:AU) (CHEOY) to Outperform (2)CLSA analyst Andrew Paine upgraded Cochlear Ltd. (COH:AU) (OTC: CHEOY) from Hold (3) to Outperform (2) with a price target of AUD290.00 (from AUD282.50).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$187.81

Hold

7.93%

Upside

Reiterated

01/08/26

Ord Minnett Sticks to Its Hold Rating for Cochlear (CHEOF)

Laura Sutcliffe

Citi

$213.88→$200.51

Hold

15.22%

Upside

Reiterated

12/08/25

Analysts Offer Insights on Healthcare Companies: Cochlear (Other OTC: CHEOF) and Relmada Therapeutics (NASDAQ: RLMD)

Shane Storey

Canaccord Genuity

$220.56

Buy

26.75%

Upside

Reiterated

11/17/25

Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)

David Bailey

Morgan Stanley

$187.14

Sell

7.54%

Upside

Reiterated

10/17/25

Cautious Outlook on Cochlear: Sell Rating Due to FY26 NPAT Reliance and Nexa Implant Uncertainty

David Low

J.P. Morgan

$203.85→$232.59

Buy

33.66%

Upside

Reiterated

08/18/25

J.P. Morgan Remains a Buy on Cochlear (CHEOF)

Unknown Analyst

Macquarie

Not Ranked

Macquarie

$180.79→$197.77

Hold

13.65%

Upside

Reiterated

08/18/25

Macquarie Reaffirms Their Hold Rating on Cochlear (CHEOF)

Derek Jellinek

Morgans

$188.05→$200.2

Sell

15.05%

Upside

Downgraded

08/17/25

Cochlear (CHEOF) was downgraded to a Sell Rating at Morgans

David Stanton

Jefferies

$236.6→$237.94

Buy

36.73%

Upside

Reiterated

08/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Recursion Pharmaceuticals (NASDAQ: RXRX) and Cochlear (Other OTC: CHEOF)

Steven Wheen

Jarden

$180.65→$186.15

Hold

6.97%

Upside

Reiterated

08/15/25

Jarden Keeps Their Hold Rating on Cochlear (CHEOF)

Craig Wong-Pan

RBC Capital

$196.5→$197.17

Hold

13.30%

Upside

Reiterated

08/15/25

RBC Capital Reaffirms Their Hold Rating on Cochlear (CHEOF)

Marcus Curley

UBS

$217.22→$233.93

Buy

34.43%

Upside

Reiterated

08/15/25

UBS Sticks to Their Buy Rating for Cochlear (CHEOF)

Davinthra Thillainathan

Goldman Sachs

Hold

―

Reiterated

06/14/25

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (NASDAQ: TNDM) and Cochlear (Other OTC: CHEOF)

Andrew Paine

CLSA

$188.81→$193.83

Buy

11.38%

Upside

Upgraded

03/17/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cochlear

3 Months

xxx

Success Rate

4/7 ratings generated profit

Average Return

+2.50%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.50% per trade.

1 Year

David StantonJefferies

Success Rate

3/6 ratings generated profit

Average Return

-8.60%

reiterated a buy rating 5 months ago

Copying David Stanton's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.60% per trade.

2 Years

xxx

Success Rate

3/6 ratings generated profit

Average Return

-11.08%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -11.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CHEOF Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CHEOF has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CHEOF average Analyst price target in the past 3 months is 198.85.

Each month's total comprises the sum of three months' worth of ratings.

CHEOF Financial Forecast

CHEOF Earnings Forecast

Next quarter’s earnings estimate for CHEOF is $2.21 with a range of $2.21 to $2.21. The previous quarter’s EPS was $1.90. CHEOF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CHEOF has Performed in-line its overall industry.

CHEOF Sales Forecast

Next quarter’s sales forecast for CHEOF is $818.10M with a range of $818.10M to $818.10M. The previous quarter’s sales results were $791.99M. CHEOF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CHEOF has Performed in-line its overall industry.

CHEOF Stock Forecast FAQ

What is CHEOF’s average 12-month price target, according to analysts?

Based on analyst ratings, Cochlear Limited’s 12-month average price target is 198.85.

What is CHEOF’s upside potential, based on the analysts’ average price target?

Cochlear Limited has 14.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CHEOF a Buy, Sell or Hold?

Cochlear Limited has a consensus rating of Hold which is based on 1 buy ratings, 2 hold ratings and 1 sell ratings.

What is Cochlear Limited’s price target?

The average price target for Cochlear Limited is 198.85. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $220.39 ,the lowest forecast is $186.99. The average price target represents 14.27% Increase from the current price of $174.02.

What do analysts say about Cochlear Limited?

Cochlear Limited’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of CHEOF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cochlear (CHEOF) Stock Forecast & Price Target

CHEOF Analyst Ratings

CHEOF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cochlear

CHEOF Analyst Recommendation Trends

CHEOF Financial Forecast

CHEOF Earnings Forecast

CHEOF Sales Forecast

CHEOF Stock Forecast FAQ

Detailed List of Analyst Forecasts